A recently developed UM171 molecule was used in a blood transplant by a medical team on a young man suffering from severe aplastic anemia, an autoimmune disease.
Drug found to correct gene defect that causes immune-driven gut leakiness
Researchers have found that the drug tofacitinib, also called Xeljanz and approved by the FDA to treat rheumatoid arthritis and ulcerative colitis, can repair permeability defects in the intestine.
How COVID-19 could lead to runaway inflammation
A new study addresses a mystery first raised in March: Why do some people with COVID-19 develop severe inflammation? The research shows how the molecular structure and sequence of the SARS-CoV-2 spike protein could be behind life-threatening inflammato…
Common antioxidant enzyme may provide potential treatment for COVID-19
Catalase, a naturally occurring enzyme, holds potential as a low-cost therapeutic drug to treat COVID-19 symptoms and suppress the replication of coronavirus inside the body, researchers have found.
Mussels connect antibodies to treat cancer
A research team has developed an innovative local anticancer immunotherapy technology using mussel protein.
Inflammatory gene provides clue to obesity risk
A gene that helps to control inflammation increases the risk of obesity and could be turned off in mice to stop weight gain, a study has found.
Prostate cancer: immunotherapy offers hope
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasized, castration-resistant prostate cancer. This is the finding of the long-term analyses of an international phase 3 clinical trial. The stud…
VirScan offers new insights into COVID-19 antibody response
VirScan, a technology that can determine which of more than 1,000 different viruses have infected a person, can now also detect evidence of infection from coronaviruses, including SARS-CoV-2.
Successful TB vaccine moves forward after phase 2 trial
Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today. The three-year trial was conducted among 650 adolescents in Tanzania, a nation with high rates of TB infection, and showed that the vaccine was safe and induc…
Strong activation of anti-bacterial T cells linked to severe COVID-19
A type of anti-bacterial T cells, so-called MAIT cells, are strongly activated in people with moderate to severe COVID-19 disease, according to a new study.